Through the survival analysis in GBM (WHO grade IV), we found that the high expression levels of PRMT2 are significantly correlated with unfavorable prognosis of patients in all datasets that we analyzed (TCGA, CGGA, REMBRANDT) (Fig. 1d). The gene discussed is PRMT2; the disease is glioblastoma.